T2 Biosystems (TTOO) Stock Price, News & Analysis

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for T2 Biosystems in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" TTOO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TTOO, but not buy additional shares or sell existing shares.
View TTOO analyst ratings or view top-rated stocks.

1 analysts have issued 1 year target prices for T2 Biosystems' shares. Their TTOO share price targets range from $3.00 to $3.00. On average, they expect the company's stock price to reach $3.00 in the next twelve months. This suggests that the stock has a possible downside of 0.3%.
View analysts price targets for TTOO or view top-rated stocks among Wall Street analysts.

T2 Biosystems' stock was trading at $6.28 at the beginning of the year. Since then, TTOO shares have decreased by 52.1% and is now trading at $3.01.
View the best growth stocks for 2024 here.

T2 Biosystems saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 396,900 shares, an increase of 34.4% from the March 15th total of 295,400 shares. Based on an average trading volume of 255,400 shares, the short-interest ratio is currently 1.6 days. Approximately 11.6% of the shares of the company are sold short.
View T2 Biosystems' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Monday, May 6th 2024.
View our TTOO earnings forecast.

T2 Biosystems will be holding an earnings conference call on Monday, May 6th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

T2 Biosystems, Inc. (NASDAQ:TTOO) posted its quarterly earnings results on Thursday, November, 4th. The medical equipment provider reported ($400.00) EPS for the quarter, meeting analysts' consensus estimates of ($400.00). The medical equipment provider earned $7.43 million during the quarter. During the same quarter in the previous year, the company posted ($400.00) EPS.

T2 Biosystems shares reverse split on the morning of Friday, October 13th 2023. The 1-100 reverse split was announced on Friday, October 13th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, October 13th 2023. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

T2 Biosystems updated its fourth quarter 2023 earnings guidance on Friday, February, 16th. The company provided EPS guidance of for the period. The company issued revenue guidance of $1.7 million-$1.7 million, compared to the consensus revenue estimate of $2.4 million.

36 employees have rated T2 Biosystems Chief Executive Officer John McDonough on Glassdoor.com. John McDonough has an approval rating of 54% among the company's employees. This puts John McDonough in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other T2 Biosystems investors own include Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), VBI Vaccines (VBIV), Tonix Pharmaceuticals (TNXP), OPKO Health (OPK), SCYNEXIS (SCYX), Biocept (BIOC), Heat Biologics (HTBX), NVIDIA (NVDA) and Vaxart (VXRT).

Shares of TTOO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.